Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.68 |
| ▸ | APP | P05067 | 7/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741480 | 0.90 | MAOB (0.81) | MAOBAPPMAOARAB9ACYP19A1 | |
| SCHEMBL18664184 | 0.90 | MAOB (0.81) | MAOBAPPMAOARAB9ACYP19A1 | |
| SCHEMBL23541194 | 0.89 | MAOB (0.59) | MAOBAPPMAOARAB9ACYP19A1 | |
| SCHEMBL20000873 | 0.86 | APP (0.80) | MAOBAPPRAB9ANPC1POLB | |
| SCHEMBL23235799 | 0.85 | MAOB (0.51) | MAOBAPPMAOARAB9ACYP19A1 | |
| SCHEMBL13232462 | 0.85 | MAOB (0.68) | MAOBMAOARAB9ACYP19A1NPC1 | |
| SCHEMBL16604318 | 0.85 | MAOB (0.68) | MAOBMAOARAB9ACYP19A1NPC1 | |
| SCHEMBL14163886 | 0.85 | CYP2A6 (0.70) | MAOBAPPMAOARAB9AHRH3 | |
| SCHEMBL7316077 | 0.85 | MAOB (0.65) | MAOBMAOACYP19A1POLB | |
| SCHEMBL20053881 | 0.85 | MAOB (0.65) | MAOBMAOACYP19A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161439-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | BASSERU CHEMICAL CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
| EP-3309145-A1 | MARINE PERIPHYTON REPELLENT COMPOSITION | Basseru Chemical Co., Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20180072657-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | BASSERU CHEMICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072657-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | BASSERU CHEMICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9302981-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8669285-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445714-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263877-A1 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7989500-B2 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2066329-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | Reviva Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | REVIVA PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008034142-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0641770-B1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA CO (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-5698692-A | INHIBIT BINDING BETWEEN PLATELET MEMBRANE GLYCOPROTEIN AND FIBRINOGEN | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-12-16 | — | — | US | disclosed |
| US-5594004-A | CARDIOVASCULAR DISORDERS AND ANTICOAGULANTS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641770-A1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072657-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | CCL11, SPTLC3, C3AR1 | MAOB 2329/4885APP 4609/4885MAOA 2644/4885 |
| US-20110263704-A1 | Methods of Using Cycloalkylmethylamines | AADAC, PNMT, INMT | MAOB 141/4885APP 3464/4885MAOA 94/4885 |
| US-20190161439-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | CCL11, SPTLC3, C3AR1 | MAOB 2329/4885APP 4609/4885MAOA 2644/4885 |
| US-20140194508-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | MAOB 171/4885APP 2894/4885MAOA 98/4885 |
| US-20080139663-A1 | Cycloalkylmethylamine analogs; use treating obesity or related co-morbid indications | AADAC, GPR119, MC4R | MAOB 183/4885APP 3918/4885MAOA 145/4885 |
| US-20110263877-A1 | Cycloalkylmethylamines | AADAC, GPR119, INMT | MAOB 185/4885APP 3352/4885MAOA 122/4885 |
| US-20130231386-A1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | AADAC, INMT, AADAT | MAOB 171/4885APP 2894/4885MAOA 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.